Company Encyclopedia
View More
name
QianJin Pharmaceutical
600479.SH
ZhuZhou QianJin Pharmaceutical Co.,Ltd researches, develops, produces, and sells traditional Chinese medicines, chemicals and API, and TCM derivatives in China. The company offers TCM products, chemical medicine, derivative products, and hygienic products, including gynaecological and baby nursing, and maternity pad/ maternity package. ZhuZhou QianJin Pharmaceutical Co.,Ltd was founded in 1966 and is headquartered in Zhuzhou, China.
3.157 T
600479.SHMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
B
PharmaceuticalsIndustry
Industry Ranking54/223
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreB
    • ROE10.18%B
    • Profit Margin6.88%B
    • Gross Margin49.91%B
  • Growth ScoreC
    • Revenue YoY-2.70%D
    • Net Profit YoY-14.25%D
    • Total Assets YoY10.04%B
    • Net Assets YoY5.91%B
  • Cash ScoreC
    • Cash Flow Margin1453.19%B
    • OCF YoY-2.70%D
  • Operating ScoreB
    • Turnover0.78B
  • Debt ScoreB
    • Gearing Ratio33.80%B

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    QianJin Pharmaceutical: Subsidiary's 3 drugs are expected to be selected for national centralized procurement

    QianJin Pharmaceutical announced that its subsidiary QianJin Xiangjiang Pharmaceutical participated in the 11th batch of national centralized drug procurement, with 3 drugs expected to be selected. The price of Adenosylcobalamin capsules is 4.88 yuan/box, Fluvoxamine tablets 7.14 yuan/box, and Dopamine tablets 18.88 yuan/box, mainly supplied to Hunan, Guangxi, Guizhou, and other regions. The procurement period for selected products is until December 31, 2028

    Zhitong·
    SH
    600479
    -0.46%
    Zhitong·
    SH
    600479
    -0.46%

    QianJin Pharmaceutical: Issued 73.7029 million shares to acquire assets

    QianJin Pharmaceutical announced the issuance of 73.7029 million shares to purchase assets, with an issuance price of 8.41 yuan per share. The newly issued shares for asset purchase have completed the registration procedures at the Shanghai branch of China Securities Depository and Clearing Corporation Limited on October 23, 2025. The expected listing date is October 30, 2025

    Zhitong·
    SH
    600479
    -0.46%
    Zhitong·
    SH
    600479
    -0.46%

    QianJin Pharmaceutical acquires equity in 2 subsidiaries to accelerate resource integration

    Zhuzhou QianJin Pharmaceutical Co., Ltd. has obtained approval from the China Securities Regulatory Commission to acquire 28.92% of Hunan QianJin Xiangjiang Pharmaceutical and 68.00% of Hunan QianJin Xieli Pharmaceutical through the issuance of shares and cash payment. This is the 14th registered restructuring project approved by the Shanghai Stock Exchange this year. After the transaction, Zhuzhou Guotou's equity stake in the listed company will increase from 28.76% to 34.94%, which will help improve the quality and efficiency of state-owned assets and maintain the stability of corporate governance and control

    Zhitong·
    SH
    600479
    -0.46%
    Zhitong·
    SH
    600479
    -0.46%

    QianJin Pharmaceutical released its semi-annual performance, with a net profit attributable to the parent company of 128 million yuan, a year-on-year increase of 8.5%

    According to the Zhitong Finance APP, QianJin Pharmaceutical disclosed its semi-annual report for 2025. During the reporting period, the company achieved revenue of 1.818 billion yuan, a year-on-year decrease of 5.52%; net profit attributable to the parent company was 128 million yuan, a year-on-year increase of 8.5%; net profit excluding non-recurring gains and losses was 118 million yuan, a year-on-year increase of 6.58%; basic earnings per share were 0.3012 yuan

    Zhitong·
    SH
    600479
    -0.46%
    Zhitong·
    SH
    600479
    -0.46%

    QianJin Pharmaceutical: The restructuring matter will be discussed at the meeting on August 18

    QianJin Pharmaceutical announced that the company plans to acquire 28.92% equity in Hunan QianJin Xiangjiang Pharmaceutical and 68.00% equity in Hunan QianJin Xieli Pharmaceutical through the issuance of shares and cash payment. The Mergers and Acquisitions Review Committee of the Shanghai Stock Exchange will hold a meeting on August 18, 2025, to review the transaction application

    Zhitong·
    SH
    600479
    -0.46%
    Zhitong·
    SH
    600479
    -0.46%
    © 2025 Longbridge｜Disclaimer